This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

27/100

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Progressive neurodegeneration, which causes memory loss, cognitive decline, and functional impairment is known as Alzheimer's disease, the most common type of dementia, first identified by Alois Alzheimer in 1907. Neurites, amyloid- deposits and neurofibrillary tangles are pathological features of this condition, along with synaptic dysfunction and the death of neurons. Recent developments have led to a significant increase in the global prevalence of dementia, with estimates suggesting that up to 150 million people will be affected by the condition by 2050.However exposure to head trauma, infections, and environmental factors also plays a role in promoting the development of the Alzheimer's disease The progression Alzheimer's diseasei of occurs in three phases, mild, moderate and severe with the ultimate outcome being complete dependence on caregivers.The current pharmacological treatments, such as drugs that block acetylcholinesterase, anti-amyloid effects and selective lipoprotein receptors, calcium antagonists, antioxidants or iron chelators, provide only temporary relief.Blarcamesine a novel small-molecule sigma-1 receptor agonist and muscarinic receptor modulator, may be an effective treatment option for diseases. Through its activation of sigma-1 receptors, it provides multi-targeted neuroprotection by enhancing mitochondrial stability, decreasing oxidative stress, promoting autophagy, improving synaptic plasticity. High brain penetration and oral bioavailability are favorable pharmacokinetic traits, which further enhance its therapeutic potential. Currently, clinical studies demonstrate that Blarcamesine has the potential to enhance treatment of Alzheimer's disease by targeting neurodegeneration mechanisms beyond just symptomatic therapy.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Veeranki, M., Kiran, G. U., Gadde, P., Thumpati, P., Rompicharla, N., & Ramanadham, S. G. T. (2025). Pharmaceutical developments in alzheimer's disease: An emphasis on blarcamesine. International Journal of Pharmacology and Clinical Research. https://doi.org/10.33545/26647613.2025.v7.i2b.104

Vancouver

Veeranki M, Kiran GU, Gadde P, Thumpati P, Rompicharla N, Ramanadham SGT. Pharmaceutical developments in alzheimer's disease: An emphasis on blarcamesine. International Journal of Pharmacology and Clinical Research. 2025. doi:10.33545/26647613.2025.v7.i2b.104.

BibTeX

@article{veeranki2025-f0ce697e,
  author  = {Veeranki, Meghana and Kiran, Garlapati Usha and Gadde, Pavithra and Thumpati, Prasanna and Rompicharla, Nandini and Ramanadham, Siva Gowri Tanuja},
  title   = {{Pharmaceutical developments in alzheimer's disease: An emphasis on blarcamesine}},
  journal = {International Journal of Pharmacology and Clinical Research},
  year    = {2025},
  doi     = {10.33545/26647613.2025.v7.i2b.104},
  url     = {https://doi.org/10.33545/26647613.2025.v7.i2b.104}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Recent developments have led to a significant increase in the global prevalence of dementia, with estimates suggesting that up to 150 million people will be affected by the condition by 2050.However exposure to head trauma, infections, and environmental factors also plays a role in promoting the development of the Alzheimer's disease The progression Alzheimer's diseasei of occurs in three phases, mild, moderate and severe with the ultimate outcome being complete dependence on caregivers.The current pharmacological treatments, such as drugs that block acetylcholinesterase, anti-amyloid effects and selective lipoprotein receptors, calcium antagonists, antioxidants or iron chelators, provide only temporary relief.Blarcamesine a novel small-molecule sigma-1 receptor agonist and muscarinic receptor modulator, may be an effective treatment option for diseases.

Why it matters

This review states that current pharmacological treatments for Alzheimer's disease provide only temporary relief and describes blarcamesine, a small-molecule sigma-1 receptor agonist and muscarinic receptor modulator, as a possible treatment option. It reports no confirmed cure or prevention.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 27/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 25 of the 93 points we could judge it on, which is 27 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (International Journal of Pharmacology and Clinical Research)
Journal's citation record	0 / 4	International Journal of Pharmacology and Clinical Research: journal h-index 2 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Siva Gowri Tanuja Ramanadham holds only 2 work(s), too few to judge a track record — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multi-centre collaboration	0 / 3	OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	25 / 93	Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 93 points we could judge it on is 27 out of 100.
Total	27 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Treatments

Also in Treatments

166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →